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The Journal of Immunology
NFAT1 and JunB Cooperatively Regulate IL-31 Gene
Expression in CD4+ T Cells in Health and Disease
Ji Sun Hwang,* Gi-Cheon Kim,*,† EunBee Park,* Jung-Eun Kim,*,† Chang-Suk Chae,*
Won Hwang,*,† Changhon Lee,*,‡ Sung-Min Hwang,*,‡ Hui Sun Wang,x Chang-Duk Jun,†
Dipayan Rudra,* and Sin-Hyeog Im*,‡
IL-31 is a key mediator of itching in atopic dermatitis (AD) and is preferentially produced by activated CD4+ T cells and Th2 cells.
Although pathophysiological functions of IL-31 have been suggested in diverse immune disorders, the molecular events underlying
IL-31 gene regulation are still unclear. In this study we identified the transcription start site and functional promoter involved in
IL-31 gene regulation in mouse CD4+ T cells. TCR stimulation–dependent IL-31 expression was found to be closely linked with
in vivo binding of NFAT1 and JunB to the IL-31 promoter. Although NFAT1 alone enhanced IL-31 promoter activity, it was
further enhanced in the presence of JunB. Conversely, knockdown of either NFAT1 or JunB resulted in reduced IL-31 expression.
NFAT1-deficient CD4+ T cells showed a significant defect in IL-31 expression compared with wild-type CD4+ T cells. In agreement
with these findings, mice subjected to atopic conditions showed much higher levels of IL-31, which were closely correlated with
a significant increase in the number of infiltrated NFAT1+CD4+ T cells into the AD ears. Amelioration of AD progression by
cyclosporin A treatment was well correlated with downregulation of IL-31 expressions in CD4+ T cells and total ear residual cells.
In summary, our results suggest a functional cooperation between NFAT1 and JunB in mediating IL-31 gene expression in CD4+
T cells and indicate that interference with this interaction or their activity has the potential of reducing IL-31–mediated AD
symptoms. The Journal of Immunology, 2015, 194: 1963–1974.
I
nterleukin-31 is produced by different immune cell types such
as mast cells, eosinophils, epithelial cells, and by activated
CD4+ T cells and Th2 cells (1, 2). The IL-31 receptor is a
heterodimeric receptor composed of IL-31RA and oncostatin
M receptor-b (OSMR-b). Although IL-31 directly binds to IL-31RA,
their binding affinity is significantly increased in the presence of
OSMR-b. Binding of IL-31 to its receptor triggers JAK/STAT,
MAPK, and PI3K/AKT pathways and activates STAT1, STAT3,
and STAT5 transcription factors, which induce expression of diverse
target genes (3–5) associated with various immune disorders. IL-31
regulates proliferation and survival of myeloid progenitor cells (6)
and expression of proinflammatory cytokines and chemokines from
nonimmune cells (7, 8). Increased expression of IL-31 correlates with
pathogenesis of airway hypersensitivity by inducing the mediators
such as vascular endothelial growth factor, epidermal growth factor,
and CCL2 (8, 9). IL-31 also plays a pathogenic role in atopic der-
matitis (AD) (10, 11), and its expression is closely correlatedwith the
expression of IL-4 and IL-13 in AD patients (12–14). IL-31 transgenic
mice spontaneously develop the symptoms of AD (2). Furthermore,
enhanced levels of IL-31RA and OSMR-b are closely related with
itching behavior in AD mice (15), and treatment with anti–IL-31 Ab
inhibits the scratching behavior of the NC/Nga mouse (16).
The NFAT family consists of five members: NFAT1 (NFATc2),
NFAT2 (NFATc1), NFAT3 (NFATc4), NFAT4 (NFATc3), and
NFAT5 (TonEBP) (17). Activation of NFAT1 through NFAT4 is reg-
ulated by Ca2+ signaling and NFAT1, NFAT2, and NFAT4 are ex-
pressed in immune cells. NFAT family members consist of NFAT
homology region and REL homology region domains. The NFAT
homology region domain contains calcineurin docking sites, nuclear
localization sequence, and several inducible phosphorylation sites
(18). The REL homology region serves as a DNA binding domain
that contains Fos, Jun contact sites that allow the formation of NFAT,
Fos/Jun, and a DNA quaternary complex. Increased Ca2+ concen-
tration by TCR engagement activates calmodulin and then sequen-
tially activates the phosphatase calcineurin. Activated calcineurin
dephosphorylates NFAT in the cytosol, which leads to nuclear
translocation. NFAT positively regulates expression of various cyto-
kines (19) by binding to the regulatory elements of its target gene loci
through a formation of activation complexes with other transcription
factors, including AP-1, CEBP, GATA3, T-bet, and IFN regulatory
factor 4 (20, 21).
Although pathophysiological function of IL-31 in diverse im-
mune disorders has been suggested, the molecular mechanisms
responsible for IL-31 gene expression in CD4+ T cells and its relevance
under AD remain elusive. In the present study, we identified the
transcription start site, functional promoter region, and transcription
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factors responsible for IL-31 gene expression in CD4+ T cells. We
showed that recruitment of NFAT1 and JunB proteins to the IL-31
promoter locus significantly enhanced IL-31 promoter activity. In
experimental AD, infiltrated CD4+ T cells that produce high levels
of IL-31 expression also showed high NFAT1 levels. Additionally,
oral administration of cyclosporin A (CsA) to ADmice significantly
suppressed disease progression by decreasing IL-31 expression in
CD4+ T cells as well as total ear residual cells.
Materials and Methods
Mice and cell lines
Female BALB/c mice (6–8 wk of age) and C57BL/6 mice (6–8 wk of age)
were purchased from Japan SLC (Hamamatsu, Japan). An NFAT1-
deficient mouse line was provided by Dr. A. Rao (La Jolla Institute for
Allergy and Immunology). All mice were maintained under specific
pathogen-free conditions in the Animal Facility of the Gwangju Institute of
Science and Technology. All experimental procedures were performed in
accordance with National Institutes of Health’s Guidelines for the Care and
Use of Laboratory Animals and were approved by the Animal Care and Ethics
Committees of the Gwangju Institute of Science and Technology (permit no.
GIST-2011-3). Animals were maintained in accordance with the National
Animal Welfare Law of Korea. The murine T cell lymphoma cell line EL4
was obtained from the Korea Cell Line Bank (Seoul National University,
Seoul, Korea). Human embryonic kidney cell line HEK-293 was purchased
from Invitrogen (Grand Island, NY).
Cell culture and stimulation
Isolated primary cells were cultured in RPMI 1640medium (Welgene, Daegu,
Korea) supplemented with 10% FBS (HyClone Laboratories, Logan, UT),
3 mM L-glutamine (Sigma-Aldrich, St. Louis, MO), 100 U/ml penicillin
(Sigma-Aldrich), 100 U/ml streptomycin (Sigma-Aldrich), nonessential
amino acids (Welgene), sodium pyruvate (Welgene), HEPES (Welgene), and
0.05 mM 2-ME (Sigma-Aldrich). Ear total cells were cocultured with CD4+
T cell–depleted splenocytes with house dust mite extracts (5 mg/ml) for 24 h.
CD4+ T cells were stimulated with PMA (50 ng/ml) and/or ionomycin
(1 mM) for 2 h. CD4+ T cells were also stimulated with 1 mg/ml plate-bound
anti-CD3 (BD Biosciences, San Diego, CA), 1 mg/ml soluble anti-CD28
(BD Biosciences), or anti-CD3/anti-CD28 for 2 h. To check IL-31 mRNA
expression kinetics, cells were stimulated with PMA/ionomycin or anti-CD3/
anti-CD28 for the indicated time points. NFAT1-deficient CD4+ T cells were
stimulated with PMA/ionomycin for indicated time points to compare IL-31
expression with normal CD4+ T cells. For the inhibitor experiments, CD4+
T cells isolated from C57BL/6 mice or AD-induced mice were pretreated
with 1 mM CsA (Calbiochem, Darmstadt, Germany), 5 mM tanshinone IIA
(Santa Cruz Biotechnology, Santa Cruz, CA), CsA/tanshinone IIA, or acti-
nomycin D (Sigma-Aldrich) for 30 min, then stimulated with PMA/ionomycin
for an additional 2 h.
Isolation of CD4+ T cells and total ear residual cells
CD4+ T cells from the lymph nodes and spleen of C57BL/6 mice were iso-
lated with CD4+ T cell isolation beads (Miltenyi Biotec, Bergish Gladbach,
Germany) according to the manufacturer’s protocol. Ears were removed from
normal or AD groups, cut into three pieces, washed with RPMI 1640 medium
(Welgene), and gently stirred in flasks containing 25 ml 1.0 mM EDTA in
5% FBS (HyClone Laboratories) for 20 min at room temperature. Then ear
segments were minced, transferred into a 50-ml centrifuge tube containing
15 ml RPMI 1640 without serum, and vigorously shaken for 15 s three times.
After that, tissues were transferred into T flasks containing 10 ml 0.5 mg/ml
collagenase type V (Sigma-Aldrich) and incubated for 1 h at 37˚C in a shaking
incubator. Finally, the soup containing ear total cells was centrifuged and
washed with ice-cold PBS and cultured in T cell media. Ear residual CD4+
T cells were isolated with CD4+ T cell isolation beads according to the
manufacturer’s protocol, and flow-through was used as non–CD4+ T cells.
RACE
59-RACE was carried out by using the SMARTer RACE cDNA ampli-
fication kit (Clontech Laboratories, Mountain View, CA) according to the
manufacturer’s instructions. The primer sequences used are as follows:
first PCR (59-CCA CTT CCA GTC CCTACAGGG TAG CAG AAC AAG
ATT TCA-39), nested PCR (59-TAA CAT GAC TAG TAATGA CCG CAC
AGT-39). The resulting RACE PCR products were isolated from agarose
gel by using the NucleoTrap gel extraction (Clontech), cloned into pGEM-
T Easy vector (Promega, Madison, WI), and confirmed by sequencing.
RNA isolation, cDNA synthesis, and quantitative real-time
PCR
Total RNA was extracted from cells with TRIzol reagent (Molecular Re-
search Center, Cincinnati, OH) according to the manufacturer’s protocol.
For reverse transcription, 1 mg total RNA was used and cDNA was gen-
erated using an oligo(dT) primer (Promega) and ImProm-II reverse tran-
scriptase (Promega) in a total volume of 20 ml. The mRNA level was
determined using 1 ml cDNA by real time PCR with SYBR Green using
a protocol provided by the manufacturer (Chromo4; MJ Research). Mouse
hypoxanthine phosphoribosyltransferase (HPRT) primer was used for
quantitative RT-PCR (qRT-PCR) to normalize the amount of cDNA used
for each condition. The primer sequences used are as follows: HPRT
(forward, 59-TTA TGG ACA GGA CTG AAA GAC-39; reverse, 59-GCT
TTA ATG TAATCC AGC AGG T-39), IL-31 (forward, 59-ACA ACTATA
GCA TAA AGC AGG C-39; reverse, 59-GAT TCA TCA GTA TTT CCA
GGC A-39), NFAT1 (forward, 59-GAG AAG ACT ACA GAT GGG CAG-
39; reverse, 59-ACT GGG TGG TAG GTA AAG TG-39), and JunB
(forward, 59-AGG TGA AGA CAC TCA AGG CTG AGA A-39; reverse,
59-TGA CAT GGG TCA TGA CCT TCT GCT T-39).
Plasmid construction, site-directed mutagenesis, and luciferase
reporter assays
The deletion constructs were generated by cloning the genomic sequences
upstream of the first coding exon of the IL-31 gene into the pXPG reporter
vector digested by appropriate restriction enzymes. Different combinations
of forward primers and same reverse primer in the 59 region of the tran-
scription start site of the mouse IL-31 were used to obtain the deletion
constructs and primer sequences as follows: forward, 2276 bp, 59-CGC
GGATCC GCC TGA AAG ATG CTATGTAAT CC-39; 1461 bp, 59-CGC
GGA TCC ATT AAG TAC TGA AGT AGG GCT-39; 767 bp, 59-GGA
AGA TCT TCC CAT AAT TAA CTG ATC CAC C-39; 498 bp, 59-GGA
AGATCT CCC TCT AAG TCA CTT CTT CC-39; 381 bp, 59-GGA AGA
TCT GTG GTA TGT GTA TGC GTT TGT G-39; 257 bp, 59-GGA AGA
TCT CTG GCA ACC TTT TGA AAATG-39; 194 bp, 59-GGA AGATCT
CTT TGA TCT GCT TCC TCA TGA C-39; reverse, 59-CCC AAG CTT
CCC TAA CAT GAT AAG AGC CA-39. The sequences of all the PCR-
derived constructs were confirmed by DNA sequencing. The binding sites
for NFAT1 or AP-1 (JunB) in the IL-31 promoter locus were subjected to
site-directed mutagenesis. Primers used for the generation of mutant
constructs are as follows (mutated regions are underlined): mutated (mt)
NFAT-a, forward, 59-GCA ACC TTT TGA AAA TGT GGG CTG GAG
AAA AGC TGA GC-39, reverse, 59-GCT CAG CTT TTC TCC AGC CCA
CAT TTT CAA AAG GTT GC-39; mtNFAT-b, forward, 59-GAA AAT
GTT TTC GTT AGA AAA GCT GAG C-39, reverse, 59-GCT CAG CTT
TTC TAA CGA AAA CAT TTT C-39; mtNFAT-c, forward, 59-GAG AAA
AGC TGAGCA ATG GTG GGG CCATGG GCG GGC CTT TGATC-39,
reverse, 59-GAT CAA AGG CCC GCC CAT GGC CCC ACC ATT GCT
CAG CTT TTC TC-39; mtAP-1–a, forward, 59-CTT TCC TCT CAT TAA
AGACGC AAG CAC TTT CCA AG-39, reverse, 59-CTT GGA AAG TGC
TTG CGT CTT TAA TGA GAG GAA AG-39; mtAP-1–b, forward, 59-
GTT TTC TGG AGA AAA GCG TCT CAATGG TTT TGC CAT GGG-
39, reverse, 59-CCC ATG GCA AAA CCA TTG AGA CGC TTT TCT
CCA GAA AAC-39. Plasmid DNAs were prepared by Gene All Exprep
Plasmid SV kit (GeneAll Biotechnology, Seoul, Korea) and EL4 T cells
were transiently transfected by GeneExpresso (Excellgen, Rockville, MD)
according to the manufacturers’ protocols. The total amount of transfected
DNA for each sample was normalized by adding the control vector,
pcDNA. After 18 h, cells were stimulated with PMA/ionomycin for 6 h
and then luciferase activity was accessed by the Dual-Luciferase assay
system (Promega, Madison, WI). Cotransfection of the HRE-luciferase
vector as an internal control allowed normalization of transfection by
Renilla luciferase activity. Constitutively active (CA)-NFAT1– and mtCA-
NFAT1–expressing vectors were given to us by Dr. A. Rao (La Jolla
Institute for Allergy and Immunology). CA-NFAT1 or mtCA-NFAT1
construct was transfected with the IL-31 promoter containing reporter
plasmid to EL4 T cells in the presence or absence of JunB expression
vector, and following steps are same as previously described.
Proximity ligation assay
The in situ PLA proximity ligation assay (PLA; Duolink in situ fluorescence
kit, Olink Bioscience, Uppsala, Sweden) was used to detect the interaction
between NFAT1 and JunB in CD4+ T cells. Wild-type (WT) CD4+ T cells
or NFAT1 knockout (KO) CD4+ T cells were stimulated with or without
PMA/ionomycin, followed by fixation with PFA, permeabilized, and in-
cubated with the indicated primary Abs and the PLA probes (anti-murine
and anti-rabbit IgG Abs conjugated with oligonucleotides). Ligation and
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amplification were performed according to the manufacturer’s instructions.
Imaging was performed on fixed samples with a confocal laser scanning
microscope Zeiss LSM 700 (363 oil immersion objective).
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) analysis was carried out essentially
as described (22) with minor modifications. CD4+ T cells isolated from
WT and NFAT1-deficient mice were harvested and fixed with formalde-
hyde after treating with or without PMA/ionomycin for 2 h prior to har-
vest. Chromatin was immunoprecipitated using anti-NFAT1 Ab (Santa
Cruz Biotechnology), anti-JunB Ab (Santa Cruz Biotechnology), or rabbit
IgG Ab (Sigma-Aldrich). Following reversal of crosslinks, presence of the
selected DNA sequence was assessed by real-time PCR using SYBR Freen
PCR mix. The primer sequences used in ChIP are as follows: 2359/2242
region, forward, 59-CCC TCT AAG TCA CTT CTT CC-39, reverse, 59-
CAA GGC AGA AGATTG AGT CAC-39;2116/253 region, forward, 59-
ATC TTC TGC CTT GCC TTG AG -39, reverse, 59-ATG AGG AAG CAG
ATC AAA GG-39; 21374/21179 region, forward, 59-AAA TAA AGA
GTC GTT CAG CCA GG-39, reverse, 59-AGT GAT CAATTA GCC CAG
CCT-39. As a loading control, the PCR was done directly on input DNA
purified from chromatin before immunoprecipitation. Data are presented as
the amount of DNA recovered relative to the input control.
DNA affinity purification assay
A DNA affinity purification assay (DAPA) was performed following pro-
tocols described previously with minor modifications (21). Briefly, bio-
tinylated complementary oligonucleotides were annealed in TEN (10 mM
Tris/HCl [pH 8.0], 1 mM EDTA, 100 mM NaCl) buffer. HEK-293 cells
overexpressing NFAT1 or JunB were lysed by sonication in 200 ml HKMG
(10 mM HEPES [pH 7.9], 100 mM KCl, 5 mM MgCl2, 10% glycerol,
0.1% Nonidet P-40, and 1 mM DTT) buffer containing protease and
phosphatase inhibitors (Roche Applied Science). The cellular debris was
removed by centrifugation. After that 30 mg total cell lysate was incubated
with anti-NFAT1, anti-JunB, and anti–b-actin (Abcam, Cambridge, MA)
Abs to check the expression level of NFAT1 and JunB along with that of
actin (control) by immunoblotting. The cell extracts (500 mg) were pre-
cleared with 10 ml M-280 streptavidin beads (Invitrogen) for 1 h at 4˚C
with gentle agitation. The cleared nuclear extracts were then incubated
with 1 mg biotinylated double-stranded probes and 10 mg poly(dI-dC)
overnight. Ten microliters M-280 streptavidin beads was used to pull down
bound proteins for 1 h at 4˚C with gentle agitation. The beads were washed
four times with cold HKMG buffer. SDS sample buffer was then added to
the beads. The samples were boiled for 5 min and subjected to SDS-PAGE
and Western blotting with anti-NFAT1 and anti-JunB (Santa Cruz Bio-
technology) Abs. Blots were developed using HRP-conjugated secondary
Ab (Sigma-Aldrich) and the an ECLWestern blot detection kit (Amersham
Pharmacia Biotech, Arlington Heights, IL). The probe sequences used for
DAPA are as follows: NFAT-a, forward, 59-CAA GCA CTT TCC AAG
AAA AGA GAG ATG C-39, reverse, 59-GCA TCT CTC TTT TCT TGG
AAA GTG CTT G-39; NFAT-b, forward, 59-CAA CCT TTT GAA AAT
GTT TTC TGG AGA AAA-39, reverse, 59-TTT TCT CCA GAA AAC
ATT TTC AAA AGG TTG-39; NFAT-c, forward, 59-AAG CTG AGC AAT
GGT TTT GCC ATG GGC GGG-39, reverse, 59-CCC GCC CAT GGC
AAA ACC ATT GCT CAG CTT-39; NFAT consensus, forward, 59-CCC
AAA GAG GAA AAT TTG TTT CAT-39, reverse, 59-ATG AAA CAA
ATT TTC CTC TTT GGG-39; AP-1–a, forward, 59-TCC TCT CAT TAA
ATC AGC AAG CAC TTT CCA-39, reverse, 59-TGG AAA GTG CTT
GCT GAT TTA ATG AGA GGA-39; AP-1–b, forward, 59-TCT GGA GAA
AAG CTG AGC AAT GGT TTT G-39, reverse, 59-CAA AAC CAT TGC
TCA GCT TTT CTC CAG A-39; mtNFAT-a, forward, 59-CAA GCA CGG
GCC AAG AAA AGA GAG ATG C-39, reverse, 59-GCA TCT CTC TTT
TCT TGG CCC GTG CTT G-39; mtNFAT-b, forward, 59-CAA CCT TTT
GAA AAT GTT TTC GTT AGA AAA-39, reverse, 59-TTT TCT AAC
GAA AAC ATT TTC AAA AGG TTG-39; mtNFAT-c, forward, 59-AAG
CTG AGC AAT GGT GGG GCC ATG GGC GGG-39, reverse, 59-CCC
GCC CAT GGC CCC ACC ATT GCT CAG CTT-39; mtAP-1–a, forward,
59-TCC TCT CAT TAA AGA CGC AAG CAC TTT CCA-39, reverse, 59-
TGG AAA GTG CTT GCG TCT TTA ATG AGA GGA-39; mtAP-1–b,
forward, 59-TCT GGA GAA AAG CGT CTC AAT GGT TTT G-39, re-
verse, 59-CAA AAC CAT TGA GAC GCT TTT CTC CAG A-39.
Small interfering RNA transfection assay
The predesigned small interfering RNAs (siRNAs) for NFAT1 (sc-36056),
JunB (sc-35727), and control siRNA (sc-37007) were purchased from Santa
Cruz Biotechnology. For siRNA transfection, effector T cells were subjected to
nucleofection (Amaxa Nucleofector; Lonza, Walkersville, MD) according to
the manufacturer’s protocol. Briefly, effector T cells were resuspended in
mouse T cell nucleofection solution at a density of 2 3 106 per 100 ml. In
each transfection, 100 ml cell suspension was mixed with 1 mM siRNA,
transferred into a cuvette, and pulsed in a Nucleofector device using program
X-001. The cells were then transferred into a 12-well plate and plated in 1 ml
prewarmed medium. Forty-six hours after transfection, the cells were treated
with PMA/ionomycin for 2 h and harvested. mRNA isolation and cDNA
synthesis was performed following the protocol described before, and
knockdown efficiency was determined by qRT-PCR and Western blot. Rel-
ative band intensity (intensity of NFAT1 or JunB/intensity of b-actin) of each
sample was analyzed by ImageJ software. For ChIP analysis, effector T cells
were transfected with control siRNA or JunB siRNA. Forty-six hours after
transfection, the cells were stimulated with PMA/ionomycin for 2 h and
harvested to perform an NFAT1 ChIP assay.
NFAT1 overexpression and reconstitution
Isolated CD4+ T cells from WT C57BL/6 or NFAT1-deficient mice were
stimulated with anti-CD3/anti-CD28 in the presence of rIL-2 (100 U/ml)
for 3 d, then cultured in only IL-2–containing complete T cell media.
NFAT1, JunB, or NFAT1 and JunB were transfected into effector T cells by
an Amaxa Nucleofector (Lonza) according to the manufacturer’s protocol.
After 22 h of transfection, cells were stimulated with PMA/ionomycin for
2 h and IL-31 mRNA level was measured by real-time PCR. In this experi-
ment, GFP-expressing vector was used as a control. Protein expression levels
of NFAT1 in WT CD4+ T cells, NFAT1-deficient CD4+ T cells, and NFAT1-
reconstituted NFAT1-deficient CD4+ T cells were measured by Western blot,
and b-actin was used as a loading control. Relative band intensity (intensity of
NFAT1/intensity of b-actin) of each sample was analyzed by ImageJ software.
Preparation of total cell lysate and nuclear extract
Cells werewashedwith ice-cold PBS and resuspended inRIPA buffer (50mM
Tris-HCl [pH 8.0], 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate)
containing protease inhibitors and 1% Nonidet P-40. Cells were allowed to
swell by incubation on ice for 20min, and then the homogenatewas centrifuged
for 5 min. The supernatant containing total cell lysate was transferred to new
tubes and used for immunoblotting. Nuclear extract was prepared with NE-
PER nuclear and cytoplasmic extraction reagents (Thermo scientific,
Waltham, MA) according the to manufacturer’s protocol. The supernatant
containing nuclear extract was used for immunoblotting.
Induction of AD and treatment of CsA
Induction of experimental AD was performed by following a protocol de-
scribed previously (23). Briefly, surfaces of both ear lobes of female BALB/c
mice (6–8 wk of age) were stripped five times with surgical tape (Nichiban,
Tokyo, Japan). After stripping, 20 ml 2% 2,4-dinitrochlorobenzene (DNCB)
(Sigma-Aldrich) dissolved in acetone/olive oil (1:3) solution was painted on
each ear. After 3 d, 20 ml 10 mg/ml mite extract (Dermatophagoides farinae;
GREER, Lenoir, NC) dissolving in PBS containing 0.5% Tween 20 was
repainted. Challenge of DNCB and mite extract was repeated once a week
alternatively until 5 wk. Only tape stripping and PBS painting were per-
formed in the normal group. To examine the effect of CsA, the micro-
emulsion form of CsA (5 mg/kg/d; Novartis, New York, NY) was orally
administrated to BALB/c mice 5 d/wk for 4 wk during the period of AD
induction. The same volume of DMSO was treated as a control.
Immunohistochemistry
Ears from AD-induced mice, normal mice, control AD–induced mice, and
CsA-treated AD-induced mice were fixed with 4% paraformaldehyde in PBS
(pH 7.4). Fixed tissues were washed in sucrose solution with several changes
(10% sucrose in PBS for 4 h, 15% sucrose in PBS for 4 h, and 20% sucrose in
PBS overnight) and were frozen in OCT compound (Sakura Finetek, Leiden,
The Netherlands). Cryostat sections (10 mm) were mounted on Superfrost Plus
slides and dried overnight at room temperature. Slides were permeabilized
with 0.1% Triton X-100 in 1% normal goat serum (NGS) for 15 min and then
blocked with 5% NGS for 1 h at room temperature. After washing with TBS,
sections were incubated overnight at 4˚C with the following primary Abs:
mouse anti-NFAT1 mAb (1:50 in 1% NGS; Santa Cruz Biotechnology), rabbit
anti–IL-31 mAb (1:50 in 1% NGS; Abcam, Cambridge, U.K.), and rat anti-
CD4 mAb (1:100 in 1% NGS; Santa Cruz Biotechnology). They were then
washed with TBS and the sections were incubated for 1 h at room temperature
with the following corresponding secondary Abs: Alexa Fluor 405 goat anti-
mouse IgG (1:1000; Invitrogen), Alexa Fluor 488 donkey anti-rabbit IgG
(1:1000; Invitrogen), and Alexa Fluor 594 goat anti-rat IgG (1:1000; Invi-
trogen). Nucleus was counterstained with DAPI (1:3000; Invitrogen) for 5 min
at room temperature. Sections were washed and then mounted with fluores-
cence mounting medium (Dako, Seoul, Korea).
The Journal of Immunology 1965
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Computational analysis of the conserved nucleotide sequence
locus
To identify a potential regulatory locus, comparative genomic analysis was
performed. Genomic sequences spanning the IL-31 gene were analyzed
using the Web-based alignment software VISTA browser 2.0 (23). Tran-
scription factor binding sites were identified using the rVISTA 2.0 software
(24), which uses matrices of the TRANSFAC database (25). Putative
recognition sites for regulatory factors were also identified by searching
the JASPAR database (26) and verified from previously reported literature.
Statistical analysis
A two-tailed Student t test was used. A p value ,0.05 was considered
statistically significant.
Results
TCR stimulation–dependent IL-31 gene expression
To investigate the underlying mechanism of IL-31 gene expression
in CD4+ T cells, we analyzed the IL-31 mRNA expression profile.
CD4+T cells isolated fromspleen and lymphnodes ofC57BL/6mice
were either unstimulated or stimulated with TCR signaling (anti-
CD3/anti-CD28) or PMA/ionomycin, along with related controls.
Relative levels of IL-31 mRNA expression were analyzed by qRT-
PCR. IL-31 expression was significantly increased upon anti-CD3/
anti-CD28 or PMA/ionomycin stimulation (Fig. 1A). To testwhether
IL-31 expression is regulated at the transcriptional level,we tested the
effect of actinomycin D, an inhibitor of mRNA synthesis. Indeed,
pretreatmentwith actinomycinD significantly decreased IL-31mRNA
expression upon PMA/ionomycin stimulation (Fig. 1B). Next, we
determined the expression kinetics of IL-31 mRNA expression. CD4+
T cells were stimulated with anti-CD3/anti-CD28 or PMA/ionomycin
for the indicated time points. Stimulation with PMA/ionomycin or
anti-CD3/anti-CD28 for 2 h significantly increased IL-31 expression
(PMA/ionomycin, 290-fold; anti-CD3/anti-CD28, 105-fold) (Fig. 1C)
measured by qRT-PCR, and relative expression level was visualized as
the agarose gel image (Fig. 1D). These results suggest that IL-31 ex-
pression is regulated through TCR signaling at the transcription level.
Identification of the transcription start site and promoter
region
To identify the transcription start site (TSS) at the mouse IL-31 gene
locus, we employed the SMART 59-RACE technique. mRNA iso-
lated from CD4+ T cells was amplified with the gene-specific
primer (corresponds to the exon 3 region of the IL-31 gene) and
the universal primer mix (Fig. 2A). RACE PCR produced one major
IL-31 transcript in CD4+ T cells (Fig. 2B). To determine the loca-
tion of the TSS, RACE transcript was isolated, sequenced, and
alignment of the sequenced RACE products to the mouse genome
was performed along with GenBank (GenBank accession no.
NM029594; http://www.ncbi.nlm.nih.gov/nuccore/NM_029594.1).
TSS was aligned with 60 bp upstream of translation start site, ATG
(Fig. 2C). Next, to identify the potential regulatory elements in the
59 region of the IL-31 gene, we performed a comparative genomic
sequence analysis. rVISTA 2.0 and TRANSFAC database analysis
revealed several potential regulatory elements that have highly con-
served noncoding sequences between humans and mice (Fig. 3A).
These include TSS, TATA box, and predicted transcription factor
binding sites (Fig. 3B). To identify the core cis-regulatory elements
we generated a series of deletion constructs as depicted in Fig. 3C.
DNA fragments encompassing various 59 upstream regions of the
IL-31 gene were cloned into the luciferase reporter vector (Fig. 3C).
These constructs were transiently transfected into EL4 T cells, and
their relative reporter activities were compared. The functional pro-
moter region was mapped in the 2359/+141 region (498-bp con-
struct) that showed maximal promoter activity upon PMA/ionomycin
stimulation (Fig. 3C). Interestingly, further deletion of the functional
promoter region significantly decreased its promoter activity as shown
in the2242/+141 region (381-bp construct) and the253/+141 region
(194-bp construct), suggesting that the 2359/+141 region may serve
as a core IL-31 promoter in CD4+ T cells.
Functional cooperation between NFAT1 and JunB to activate
IL-31 expression
To identify the key transcription factors responsible for TCR
stimulation–dependent IL-31 promoter activity, we performed
sequence analysis of the identified 2359/+141 functional pro-
moter region of the IL-31 gene. Indeed, we could identify highly
conserved binding sites for AP-1, NFAT, and NF-kB (Fig. 3B). To
delineate which transcription factors play a major role in activa-
tion of IL-31 promoter, a luciferase reporter assay was performed
in the presence of different combinations of transcription factors.
FIGURE 1. TCR stimulation induces IL-31 expres-
sion in CD4+ T cells. (A) CD4+ T cells were stimulated
under indicated conditions and relative IL-31 expression
level was measured by qRT-PCR analysis. (B) CD4+
T cells pretreated with actinomycin D (ActD) for 30 min
were stimulated with PMA/ionomycin for 2 h, and
relative IL-31 expression level was measured by RT-
PCR. (C) CD4+ T cells were stimulated with anti-CD3/
anti-CD28 or PMA/ionomycin (P/I) for indicated time
points and then subjected to qRT-PCR analysis. Mouse
HPRT was used as an internal control, and relative
IL-31 level compared with control sample is presented
in (A) through (C). (D) IL-31 and HPRT mRNA ex-
pressions were analyzed by qRT-PCR upon stimulation
and were visualized in agarose gel. Error bars indicate
SD. Data are representative of three independent ex-
periments. *p , 0.05, **p , 0.005, ***p , 0.001.
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EL4 T cells were transiently transfected with an IL-31 promoter–
driven luciferase construct along with empty vector, vectors encod-
ing members of the AP-1 family (JunB, c-Jun, and c-Fos), or NFAT
family (NFAT1, NFAT2, and NFAT4). Among them, NFAT1 over-
expression significantly enhanced IL-31 promoter activity (Fig. 4A)
in a dose-dependent manner (Fig. 4B). However, other factors such
as NFAT2, NFAT4, JunB, c-Jun, and c-Fos failed to activate the
IL-31 promoter (Fig. 4A). Because NFAT protein functions with
other interacting partners to regulate its target gene expression (27),
we tested whether NFAT1 could further enhance its IL-31 tran-
scriptional activity through a coordinate interaction with AP-1 pro-
tein that has a binding site near the NFAT binding site at the IL-31
promoter (Fig. 3B). An IL-31 promoter–driven luciferase construct
was transfected with NFAT1 alone or in combination with each
family of AP-1 proteins, and transactivity was measured by a lucif-
erase assay. Cotransfection of NFAT1 and JunB synergistically in-
creased promoter activity compared with the activity of single
transfection (Fig. 4C). Even though c-Jun and c-Fos also showed
FIGURE 2. Determination of the transcription start
site of the IL-31 gene locus. (A) Schematic diagram of
RACE analysis. The positions of exons (E) in IL-31
genomic locus are shown. The gene specific primer
(GSP, arrow) used in 59-RACE is located in exon 3
(E3). (B) After performing 59-RACE, the PCR product
was analyzed and its size was determined by arose
gel electrophoresis (black arrow). (C) The 59-RACE
product was cloned into the pGEM-T vector and se-
quenced. Analyzing the DNA sequence (GenBank ac-
cession no. NM029594) revealed a major TSS assigned
to the G nucleotide 60 bp upstream of the translation
start site (ATG). Data are representative of three in-
dependent experiments. M, marker; R, RACE product.
FIGURE 3. Identification of the functional promoter region of the IL-31 gene. (A) ECR browser analysis of the mouse and human IL-31 loci is shown.
The mouse genomic sequence is used as the base sequence on the x-axis. Schematic representation of the genomic positions of exons (E) and putative
binding sites of transcription factors and TATA box in the 59-end region of the IL-31 gene are shown. (B) 59-End genomic sequence of mouse IL-31 gene
locus with TSS indicated in bold type and black arrow and designated as +1. Locations of the deletion constructs are indicated in blue. TATA box (TATA),
translation start site (ATG), and putative binding sites for transcription factors (AP-1, NFAT, and NF-kB) are indicated and boxed. STAT6 binding site in the
human IL-31 promoter is underlined in red. (C) EL4 T cells were transfected with the control mock vector or indicated deletion constructs. Cells were
unstimulated or stimulated with PMA/ionomycin for 6 h and then relative luciferase activity (RLA) was expressed as fold difference relative to the
unstimulated mock sample. The genomic location and size of each deletion construct are specified. Error bars indicate SD. Data are representative of three
independent experiments. *p , 0.05, **p , 0.005.
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a synergistic effect with NFAT1 in IL-31 promoter activity, JunB
showed a more significant effect compared with other AP-1 proteins.
Therefore, we decided to focus on the synergistic effect between
NFAT1 and JunB for IL-31 gene expression. We also tested whether
STAT6 could activate the mouse IL-31 promoter because STAT6
was reported as a key transcription factor for enhancing the human
IL-31 promoter activity (24). Unlike in the human IL-31 promoter,
NFAT2 and STAT6 failed to activate the mouse IL-31 promoter, and
NFAT1 alone sufficiently activated the mouse IL-31 promoter in a
STAT6-independent manner (Supplemental Fig. 1B). Overexpression
of constitutively active form of NFAT1 (25) enhanced IL-31 pro-
moter activity and cotransfection of CA-NFAT1 and JunB further
enhanced IL-31 promoter activity. However, cotransfection of mtCA-
NFAT1 (25), a mutant CA-NF1 that has a mutation in the AP-1
binding sites, with JunB failed to exert a functional synergism
(Fig. 4D). Deletion of NFAT and AP-1 binding sites in the functional
promoter (2359/2116 region) significantly reduced its promoter
activity as observed in the 2116/+141 region (257-bp construct)
reporter vector (Fig. 4E). To further confirm the importance of NFAT
and AP-1 transcription factors on IL-31 promoter activity, NFAT or
AP-1 (JunB) binding sites were mutated in the functional promoter
(2359/+141 region) individually or in combination as shown in
Fig. 4F. Promoter activity was significantly decreasedwhen amutation
was introduced in the NFAT binding site located in the 2359/2116
region and 2116/+141 region. In the case of AP-1 (JunB), single
mutation of each AP-1 binding site decreased the promoter activity.
Interestingly, IL-31 promoter activity was significantly reduced when
all of the NFATand AP-1 binding sites were mutated (Fig. 4F). These
results suggest that although NFAT1 plays a major role in activation of
IL-31 promoter, AP-1 (JunB) provided an additive effect on TCR-
induced IL-31 promoter activity.
Physical binding of NFAT1 and JunB to the IL-31 promoter
locus
To test whether the functional synergism between NFAT1 and JunB
results from protein–protein interaction between them, we per-
formed a PLA in CD4+ T cells. Under unstimulated condition, a
PLA signal was detected only in the cytoplasmic region, and more
distinct signals were observed in the nucleus upon PMA/ionomycin
stimulation (Fig. 5A). In contrast, there was no detectable PLA
signal when WT CD4+ T cells were incubated with only NFAT1 Ab
(Fig. 5B) or NFAT1 KO CD4+ T cells that were incubated with both
NFAT1 and JunB Abs (Fig. 5C). These results suggest that NFAT1
FIGURE 4. NFAT1 and JunB cooperatively transactivate the IL-31 promoter. (A–C) EL4 cells were transfected with control vector (mock) or luciferase
reporter constructs driven by the IL-31 promoter (2359/+141 region, 498-bp construct) along with expression plasmids encoding NFATs (NFAT1 [N1],
NFAT2 [N2], and NFAT4 [N4]), AP-1 (JunB [JB], c-Jun [CJ], and c-Fos [CF]), and NF-kB (p65) (NK) or their combinations as indicated. Cells were
stimulated with PMA/ionomycin for 6 h and harvested for luciferase assay. (B) The NFAT1 dose-dependent effect was analyzed (300 [+], 600 [++], and
900 [+++] ng). Cells were stimulated with PMA/ionomycin for 6 h and harvested for the luciferase assay. (D) EL4 cells were transfected with luciferase
reporter construct driven by the IL-31 promoter along with expression plasmids encoding CA-NFAT1 (CA-NF1) or mtCA-NFAT1 (mtCA-NF1, which has
mutations in AP-1 binding site) in the presence or absence of JunB-expressing plasmid, as indicated. Cells were stimulated with PMA/ionomycin for 6 h
and harvested for the luciferase assay. Relative luciferase activity (RLA) of each sample to control sample (mock) is presented. (E) The 257-bp construct
(2116/+141 region) or 498-bp construct (2359/+141 region) was transfected to EL4 cells along with the indicated expression plasmids, stimulated with
PMA/ionomycin, and then the relative luciferase assay was measured. The binding sites for AP-1 (filled triangle) or NFAT (gray-filled circle) are shown.
(F) Various combinations of mutations were introduced into the IL-31 promoter reporter construct as indicated; X, mutated site in NFAT1 (N) or JunB (A)
binding sites in Fig. 3B: mtNa, mtNb, mtNc, mtNbNc, and mtNaNbNc indicate mutations in the NFAT binding sites alone or in combination in NFAT-a,
NFAT-b, and NFAT-c, respectively; mtAa, mtAb, and mtAaAb indicate mutations in the AP-1 binding sites alone or in combination in AP-1–a and AP-1–b,
respectively; mtNaAa indicates mutations in NFAT-a and AP-1–a; mtNbAbNc indicates mutations in NFAT1-b, AP-1–b and NFAT-c; mt-all indicates mutations
in all of the AP-1 and NFAT1 binding sites. Each mutant construct was transfected in EL4 cells, stimulated with PMA/ionomycin for 6 h, and then the RLAwas
measured. RLA activity was expressed as a fold difference relative to the control sample (mock). Error bars indicate SD. Data are representative of three
independent experiments. *p , 0.05, **p , 0.005, ***p , 0.001.
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and JunB interact in primary CD4+ T cells. Following this, to detect
a physical binding of NFAT1 to the predicted NFAT binding sites on
the IL-31 promoter, we performed ChIP experiments using Abs for
NFAT1 and JunB. In vivo binding of NFAT1 (Fig. 6A) and JunB
(Fig. 6B) to the 2359/2116 and 2116/253 region was confirmed
in CD4+ T cells, and their binding to the loci was further enhanced
FIGURE 5. Physical interaction between NFAT1 and JunB in primary CD4+ T cells. (A) NFAT1/JunB association was visualized in WT CD4+ T cells
with an in situ proximity ligation assay as described inMaterials and Methods. CD4+ T cells were stimulated with (+) or without (2) PMA/ionomycin (P/I)
for 2 h, after which they were subjected to PLA. Red staining indicates an NFAT1/JunB interaction, and DAPI was used to visualize the nuclei (blue). (B)
WT CD4+ T cells were treated as described in (A) without anti-JunB Ab. (C) NFAT1 KO CD4+ T cells were used and all of the procedures were same as is
(A). The top panels are overviews at lower magnification, whereas in the lower panels images are shown at a higher magnification of the white square in the
upper panels. Images are representative of three independent experiments. Scale bars, 5 mm.
FIGURE 6. In vivo binding of NFAT1 and JunB to the IL-31 promoter locus. (A and B) ChIP assay was performed with unstimulated (w/o) or PMA/
ionomycin-stimulated (P/I) CD4+ T cells using control IgG, anti-NFAT1 Ab (A) or anti-JunB Ab (B). (C) ChIP assay was performed with unstimulated (w/o) or
PMA/ionomycin-stimulated (P/I) CD4+ T cells isolated from WTor NFAT1 KO mice using control IgG or anti-JunB Ab. (D) Activated T cells were transfected
with control or JunB siRNA. After 46 h of transfection, cells were stimulated with PMA/ionomycin for 2 h and harvested to analyze NFAT1 binding. The
amounts of precipitated DNAwere measured by qRT-PCR with primers specific for the indicated NFAT/JunB binding regions (2116/254,2359/2242) in the
IL-31 promoter locus (A–D) and negative control locus (21374/21179) (C and D). Relative enrichment of the IL-31 promoter in the precipitated samples
compared with total chromatin (input) is shown. Negative images of ethidium bromide–stained gels are also shown in the right panel. C-siRNA, control siRNA;
J-siRNA, JunB siRNA. Error bars indicate SD. Data are representative of three independent experiments. *p , 0.05, **p , 0.005.
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by PMA/ionomycin stimulation (Fig. 6A, 6B). Next, we examined
whether the binding of NFAT1 and JunB to the IL-31 promoter region
was dependent on one another. To address this question we first
compared the binding of JunB to the IL-31 promoter in WT CD4+
T cells and NFAT1-deficient CD4+ T cells with or without PMA/
ionomycin stimulation. Compared to WT, in NFAT1 KO CD4+
T cells, the binding of JunB to the IL-31 promoter was significantly
decreased in only the unstimulated condition (Fig. 6C). We also ex-
amined the effect of JunB-dependent NFAT1 binding to the IL-31
promoter by knockdown of JunB expression with siRNA treatment.
Binding of NFAT1 to the IL-31 promoter was significantly reduced in
JunB siRNA–treated cells as compared with control siRNA–treated
cells (Fig. 6D). These results indicate that binding affinity of NFAT1
and JunB to the IL-31 promoter is moderately affected by one aother.
To further confirm the physical binding of NFAT1 to the IL-31
promoter, a DAPAwas performed. Three probes for NFAT1 binding
sites were designed based on their highest matrix similarity (0.8):
NFAT-a (283/256), NFAT-b (+91/+120), and NFAT-c (+119/+148)
(Fig. 3B). A biotinylated NFAT-a (283/256) probe efficiently
pulled down NFAT1 protein from NFAT1-transfected HEK-293 cell
lysate (lane 3 in Fig. 7A). Addition of nonbiotinylated competitor
probes for NFAT-a (283/256), NFAT-b (+91/+120), and NFAT-c
(+119/+148) or consensus NFAT probe significantly reduced the
pulldown efficiency (lanes 4–7 in Fig. 7A). However, mutant probes
such as mtNFAT-a (283/256), mtNFAT-b (+91/+120), mtNFAT-c
(+119/+148), and mutated consensus competitor probe failed to
inhibit the binding of biotinylated NFAT-a probe (lanes 8–11 in
Fig. 7A). These results confirmed a physical binding of NFAT1 to
the IL-31 promoter. We also confirmed the binding of JunB to the
predicted JunB binding sites at the IL-31 promoter. The biotinylated
AP-1–a (2100/271) probe effectively pulled down the JunB protein
from JunB-transfected HEK-293 cell lysate in a dose-dependent
manner (Fig. 7B).
NFAT1 and JunB cooperatively upregulate IL-31 gene
expression in primary T cells
To further investigate the functional involvement of NFAT1 and JunB
in IL-31 gene expression, primary CD4+ T cells were transfected
with NFAT1 and JunB expression plasmids, and the IL-31 transcript
level was measured by qRT-PCR. Transfection of NFAT1 or JunB
alone increased IL-31 expression by 6- and 3.2-fold, respectively,
compared with control cells (Fig. 8A). Overexpression of both
NFAT1 and JunB further increased the IL-31 expression level by
9.8-fold compared with control cells (Fig. 8A). We also tested the
knockdown effect of NFAT1 and JunB by siRNA on IL-31 ex-
pression. Treatment of siRNA for NFAT1 specifically inhibited the
expression of NFAT1 without affecting the expression of other
NFAT family members (NFAT2 and NFAT4) (Fig. 8B). Activated
CD4+ T cells were transfected with siRNAs for NFAT1 (Fig. 8C),
JunB (Fig. 8D), or mock control, and their effects on IL-31 ex-
pression were analyzed. Indeed, knockdown of NFAT1 significantly
reduced IL-31 mRNA levels (∼40% reduction in Fig. 8E), whereas
knockdown of JunB alone failed to do so. Interestingly, however,
knockdown of both NFAT1 and JunB significantly reduced IL-31
expression levels (∼80% reduction in Fig. 8E). These results indi-
cate that NFAT1 and JunB cooperatively regulate endogenous IL-31
expression in CD4+ T cells. Next, we also examined the effect of
NFAT1 and JunB on the IL-31 expression by the treatment of CsA
or tanshinone IIA, inhibitors for calcineurin and AP-1, respectively.
Indeed, CsA or tanshinone IIA treatment decreased IL-31 mRNA
production by 85 and 40%, respectively. Treatment of both CsA and
tanshinone IIA further diminished IL-31 levels by up to 90%
(Fig. 8F). To further confirm the pivotal role of NFAT1 in IL-31
expression, we tested the effect of NFAT1 deficiency on IL-31
mRNA level. Compared with CD4+ T cells from WT mice,
NFAT1-deficient (N1 KO) CD4+ T cells showed a significant de-
crease in IL-31 mRNA level upon PMA/ionomycin stimulation
(Fig. 8G). We also tested whether reconstitution of NFAT1 into
NFAT1-deficient CD4+ T cells could restore the IL-31 expression.
NFAT1-expressing plasmid was nucleofected to CD4+ T cells de-
rived from NFAT1 KO mice and after 22 h of nucleofection, and
cells were stimulated with PMA/ionomycin for 2 h. Reconstitution
efficiency of NFAT1 into NFAT1-deficient CD4+ T cells was con-
firmed by checking the protein level of NFAT1 by Western blotting
(Fig. 8H, lower panel). Upon reconstitution of NFAT1 into NFAT1
KO CD4+ T cells, the IL-31 level was partially restored compared
with NFAT1 KO CD4+ T cells. Additionally, expression levels of
two other well-studied NFAT1 target genes were also partially re-
stored by the reconstitution of NFAT1 to NFAT1 KO CD4+ T cells
(Fig. 8H, right two panels). These results indicate a crucial role of
NFAT1 for IL-31 expression in CD4+ T cells.
Essential role of NFAT1 for the IL-31 induction in AD
condition
The IL-31 level is highly increased in AD patients compared with
healthy controls (28–30), and treatment with calcineurin inhibitors
such as CsA and FK-506 ameliorates atopic symptoms (26).
However, the underlying mechanism of increased IL-31 expression
in the AD condition is still unclear. To examine the in vivo rele-
vance of NFAT1-mediated IL-31 gene regulation in the AD con-
dition, we induced experimental AD to ears of BALB/c mice using
mite extracts and DNCB. Five weeks after AD induction, CD4+
T cells from normal healthy mice or AD-induced mice were
stimulated with PMA/ionomycin or anti-CD3/anti-CD28 for 2 h.
FIGURE 7. In vitro binding of NFAT1 and JunB to the IL-31 promoter
locus. (A and B) Left, Controls for overexpression of NFAT1 and JunB
in HEK-293 cells and b-actin level (loading control). (A) Right, Biotin-
conjugated probe corresponding to NFAT-a in Fig. 3B (Bio-NFAT-a) was
incubated with cell extract (CE) from NFAT1-overexpressing HEK-293 cells
in the presence of indicated WT or mutant nonbiotinylated competitor or
NFAT consensus (NFAT cons) probes. The protein–DNA complex was
precipitated with streptavidin (Strep) and analyzed by immunoblotting with
anti-NFAT1 Ab. (B) Right, Indicated amounts of biotin-conjugated probe
corresponding to JunB binding site in Fig. 3B (Bio-JunB) was incubated
with a lysate from JunB-overexpressing HEK-293 cells. The protein–DNA
complex was analyzed by immunoblotting with anti-JunB Ab upon strepta-
vidin-mediated precipitation. (A and B) The first lane indicates input control,
which is 2.5% of the total CE used for pulldown. Error bars indicate SD. Data
are representative of three independent experiments. *p, 0.05, **p, 0.005.
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CD4+ T cells were also stimulated with mite extracts (5 mg/ml) in
the presence of T cell–depleted splenocytes as APCs for 24 h.
Compared with normal CD4+ T cells, CD4+ T cells from AD-
induced mice expressed significantly higher levels of IL-31 mRNA
upon PMA/ionomycin or anti-CD3/anti-CD28 stimulation (Fig. 9A,
left panel) or mite extract (Fig. 9A, right panel). Treatment of
inhibitors for NFAT1 (CsA) or AP-1 activity (tanshinone IIA) sig-
nificantly decreased the IL-31 expression compared with the control
(Fig. 9B). We found that IL-31–producing NFAT1+ CD4+ T cells
were highly increased in the ears of AD-induced mice as compared
with healthy mice (Fig. 9C). We found that non–CD4+ T cells also
produced much higher amounts of IL-31 under atopic conditions
(Supplemental Fig. 2). We tested whether NFAT1 also regulates
IL-31 gene expression in non–CD4+ T cells. Non–CD4+ T cells
isolated from WT and NFAT1 KO were stimulated and then rela-
tive IL-31 levels were compared. Cells from NFAT1 KO mice
showed a significant decrease in the expression level of IL-31
(Supplemental Fig. 3). IL-31 expression was significantly in-
creased in total ear residual cells from-AD induced mice as com-
pared with that of normal mice (Fig. 9D), which was well correlated
with increased NFAT1 levels in total cell lysates as well as nuclear
extract prepared from total ear cells (Fig. 9E). Increased NFAT1
levels were also found in the cells isolated from the draining lymph
nodes and spleen (Supplemental Fig. 4) of AD mice. These results
suggest that increased NFAT1 expression in cells mediates the en-
hanced IL-31 levels in AD condition. We further investigated the
functional importance of NFAT1-mediated IL-31 expression in on-
going AD mice. We tested the effect of CsA administration on IL-31
expression under the AD condition. Indeed, oral administration of
the microemulsion form of CsA significantly reduced the numbers of
IL-31–expressing CD4+ T cells in the AD ears compared with those
of control mice (Fig. 9F). Treatment of CsA significantly decreased
the expression of IL-31 as well as AD-related pathogenic cytokines
such as IL-4, IL-13, and IFN-g in the ear total cells (Fig. 9G). This
result indicates that inhibition of NFAT1 activity suppressed AD
development by reducing the IL-31 expression by CD4+ T cells and
non–CD4+ T cells as well.
Discussion
The main purpose of this study was to elucidate the molecular
mechanism of IL-31 gene regulation in CD4+ T cells in health and
disease. We identified the TSS and functional promoter region of
IL-31 gene. We found that TCR-induced IL-31 expression is medi-
ated by a functional cooperation between two transcription factors,
FIGURE 8. NFAT1 and JunB mediate endogenous IL-31 gene expression in CD4+ T cells. (A) CD4+ T cells prestimulated with anti-CD3/anti-CD28 for 48 h
were nucleofected with expression vectors encoding either NFAT1 or JunB, or in combination. Cells were then stimulated with PMA/ionomycin for 2 h and
IL-31 mRNA expression was analyzed by qRT-PCR. (B) CD4+ T cells were transfected with siRNA for control or NFAT1, and specificity of NFAT1 knockdown
was confirmed by measuring the expression of NFAT2 and NFAT4 by Western blot. Black arrows indicate the specific band for NFAT2 and NFAT4. b-Actin
was used as an internal control. (C and D) CD4+ T cells were transfected with indicated siRNAs and knockdown efficiency and specificity were confirmed by
qRT-PCR and Western blot using HPRT and b-actin as the internal loading controls, respectively. Relative density of NFAT1 or JunB band in each sample is
shown on the bottom of the gel image. C, control siRNA; J, JunB siRNA; N, NFAT1 siRNA. (E) CD4+ T cells were transfected with indicated siRNAs and
relative IL-31 level was analyzed by qRT-PCR. (F) CD4+ T cells were pretreated with CsA, tanshinone IIA (Tan), or both and were stimulated with PMA/
ionomycin (P/I) for an additional 2 h. Relative IL-31 level was analyzed by qRT-PCR. (G) CD4+ T cells isolated from WT or NFAT1-deficient (N1 KO) mice
were stimulated with PMA/ionomycin for indicated time points and subjected to RT-PCR analysis. Mouse HPRT was used as an internal control, and relative
IL-31 ratio to WTwithout stimulation is presented. (H) NFAT1 expression was restored by reconstitution of NFAT1encoding plasmid into the NFAT1-deficient
(KO) CD4+ T cells, and mRNA expression of IL-31, IL-2, and IL-4 was measured by qRT-PCR. Relative IL-31 ratio to control sample is shown. Lower panel
demonstrates the reconstitution (RC) efficiency of NFAT1 upon transfection in KO compared with its endogenous level in WT cells. b-Actin was used as an
internal control. Error bars indicate SD. Data are representative of three independent experiments. *p , 0.05, **p , 0.005, **p , 0.001.
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NFAT1 and JunB (AP-1). Physical binding of NFAT1 and JunB to
the IL-31 promoter region increased its transcriptional activity.
Under atopic conditions, enhanced infiltration of NFAT1+CD4+
T cells on the AD ears was well correlated with a significant in-
crease of IL-31 expression. Treatment of inhibitors for NFAT1 and
JunB (AP-1) significantly decreased IL-31 expression in CD4+
T cells of AD mice. Our results suggest that NFAT1 and JunB
cooperatively regulate the IL-31 transcription in CD4+ T cells in
both normal and AD conditions.
Functional importance of IL-31 in diverse immune disorders has
been suggested (27–31). However, the underlying mechanism of
IL-31 expression at the transcriptional levels is still unclear. In this
study, we have identified the TSS (Fig. 2C) and functional pro-
moter region, located between the region 2359 and +141 of the
IL-31 gene (Fig. 3C). A previous study on human IL-31 reported
a functional promoter region in CD4+ T cells and mast cells (32)
without revealing an exact TSS. We compared human and mouse
promoter regions and transcription factors responsible for the
activation of promoters (Supplemental Fig. 1A). The human IL-31
promoter (827 bp) contains conserved binding sites for several
transcription factors such as NFAT, STAT6, AP-1 and NF-kB.
Among the factors, NFAT2 and STAT6 played a major role in
activation of its promoter activity (32). We also tested whether
NFAT2 and STAT6 could activate mouse IL-31 promoter as well.
However, NFAT2 and STAT6 failed to activate mouse IL-31
promoter whereas NFAT1 alone sufficiently activated the mouse
FIGURE 9. NFAT1 mediates enhanced IL-31 expression in AD. (A) Isolated CD4+ T cells from normal (Nor) and atopic mice (AD) were untreated (w/o)
or stimulated with anti-CD3/anti-CD28, PMA/ionomycin (P/I) (left), or mite extract (right). Relative level of IL-31 expression was analyzed by qRT-PCR,
and relative IL-31 ratio to normal mice without AD (Nor) sample is presented. (B) CD4+ T cells isolated from AD-induced mice were pretreated with
indicated inhibitors for NFAT (CsA) or AP-1 (tanshinone IIA [Tan]) and their effect on IL-31 expression was measured by qRT-PCR (bottom) and vi-
sualized in agarose gel (top). (C) Triple immunohistochemical staining was performed on ear sections from normal (Nor) and AD-induced mice with Abs
against NFAT1 (blue), IL-31(green), and CD4 (red). Scale bars, 100 mm. (D) Relative IL-31 expression was analyzed in total ear cells from normal (Nor)
and AD-induced mice by qRT-PCR. (E) Protein expression level of NFAT1 in total cell lysates (TCL) and nuclear extract (N.E) of total ear cells from
normal (Nor) and AD-induced mice was measured by Western blot. b-Actin and lamin B were used as a loading control. (F) Microemulsion form of CsA
(5 mg/kg/d) was orally administrated to atopic mice. Immunohistochemical staining was performed on the ear sections of control (Cont; DMSO) and CsA-
treated (CsA) mice with anti-CD4 Ab (red) and anti–IL-31 Ab (green) and counterstained with DAPI (blue) for nuclei. Scale bars, 100 mm. (G) Total cells
isolated from ears of control (Cont) or CsA-treated (CsA) mice were either unstimulated (2) or stimulated (+) with PMA/ionomycin (P/I) for 2 h. Indicated
cytokine levels were analyzed by qRT-PCR. Relative expression of each cytokine was analyzed by comparing with the value of unstimulated (2) control
(Cont) samples. Error bars indicate SD. Data are representative of three independent experiments. *p , 0.05, **p , 0.005, ***p , 0.001.
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IL-31 promoter in a STAT6-independent manner (Supplemental
Fig. 1B). Interestingly, the STAT6 binding site identified in the hu-
man IL-31 promoter was matched with NFAT binding sites of the
mouse IL-31 promoter (Supplemental Fig. 1A). This finding sug-
gests that NFAT may play a crucial role in regulation of IL-31 ex-
pression both in humans and mice although different NFAT family
members are responsible for activation of the IL-31 promoter. In-
deed, NFAT2 and NFAT4 also showed transactivity on mouse IL-31
promoter, although NFAT1 showed the strongest activity (Fig. 4A).
Functional synergism between NFAT/AP-1 interaction has been re-
ported in regulation of diverse NFAT target genes such as IL-2, IL-4,
IL-5, IL-13, and INF-g (18, 33, 34). In this study we also found that
whereas NFAT1 alone significantly unregulated IL-31 promoter ac-
tivity, AP-1 binding had a positive contribution (Fig. 4C). Deleting
(Fig. 4E) or mutating (Fig. 4F) NFAT or AP-1 binding sites or
treating them with their inhibitors (Fig. 8F) significantly reduced
IL-31 promoter activity as well as IL-31 mRNA expression. Addi-
tionally, disruption of physical interaction between NFAT1 and AP-1
abolished the synergistic transactivity on the IL-31 promoter (Fig.
4D). These results collectively suggest a functional synergism of
NFAT1/AP-1 interaction in IL-31 gene regulation.
Pathophysiological role of IL-31 has been reported in diverse
immune disorders, including AD (32–35). Compared with normal
healthy people, a significant increase in IL-31 levels was observed
in AD patients along with the upregulation of IL-4 and IL-13 (29).
Enhanced IL-31 levels from Th2 cells activated IL-31RA–
expressing neurons, which induced a T cell–mediated itching
behavior (29, 36). Additionally, IL-31 induces the upregulation of
AD-associated pathogenic cytokines (TNF-a, IL-6, and IL-1b)
and chemokines (CXCL8, CCL2, CCL5, CXCL1, CCL18, and
CCL22) by dendritic cells, macrophages, epithelial cells, eosino-
phils, and keratinocytes (4, 37, 38). In this study, we also found
that CD4+ T cells isolated from AD mice showed a significant
increase of IL-31 expression upon TCR- or allergen (mite ex-
tract)–specific stimulation (Fig. 9) mainly in draining lymphocytes
(Supplemental Fig. 4). Immunostaining of IL-31 on sections of
AD ear showed that although CD4+ T cells are the main source of
IL-31, non–CD4+ cells also produce large amount of IL-31 as well
(Fig. 9C, Supplemental Fig. 2B). We also found that non–CD4+
T cells from NFAT1 KO mice showed a significant decrease in
IL-31 mRNA expression as compared with normal mice (Sup-
plemental Fig. 3). These results imply that NFAT1 plays a crucial
role for IL-31 gene expression in both CD4+ T cells and non–CD4+
T cells. However further studies are required to identify which kind
of NFAT proteins play a key role in regulation of IL-31 expression
in non–CD4+ T cells. Interestingly, severity of AD symptoms was
well correlated with NFAT1+ signal and IL-31 expression both in
CD4+ T cells and in non–CD4+ T cells. CsA, an inhibitor of Ca2+/
calmodulin/calcineurin/NFAT signaling had been used to treat AD
symptoms (36). CsA treatment decreases the severity of AD in
patients by inhibiting the production of several cytokines from
T cells (37, 38). In this study we found that the beneficial effect of
CsA treatment on AD suppression could be explained by an inhi-
bition of NFAT1-mediated IL-31 expression in both CD4+ T cells
and non–CD4+ T cells (Fig. 9F, 9G).
In summary, we demonstrated the NFAT1 plays a key role in
regulate of IL-31 gene expression in CD4+ T cells and non–CD4+
T cells in normal and disease conditions. Recruitment of JunB as
a cofactor for activation of the IL-31 promoter further activated
NFAT1-mediated IL-31 expression. Our results suggest that the
beneficial effect of CsA for AD treatment can be explained by
inhibition of NFAT-mediated IL-31 expression in both CD4+
T cells and non–CD4+ T cells.
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